A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors

PURPOSE: Neuroendocrine tumors (NETs) negatively impact patients’ quality of life. Octreotide long-acting release (LAR) and lanreotide depot are somatostatin analogs (SSAs) approved to treat NETs. The study objective was to explore SSA treatment experiences and preferences of patients with NETs. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Caroline, Horodniceanu, Erica, Shah, Rachel, Goldstein, Grace, Ray, David, Bennett, Bonita, Phan, Alexandria, McCarrier, Kelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135819/
https://www.ncbi.nlm.nih.gov/pubmed/35476113
http://dx.doi.org/10.1007/s00520-022-07054-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135819/
https://www.ncbi.nlm.nih.gov/pubmed/35476113
http://dx.doi.org/10.1007/s00520-022-07054-x

Ejemplares similares